## SAMPLE REPORT



## Sequential Screen First Trimester

Down Syndrome, Trisomy 18

Patient Name: Sample Patient

Referring Physician: John Doe, M.D.

Specimen #: 10000000 Patient ID: 20000000-1 Client #: 12345

DOB:00/00/1984

SSN: \*\*\*-\*\*-

Date Collected: 09/26/2012 Date Received: 09/27/2012

Lab ID: Hospital ID:

Specimen Type: Serum

City Hospital 1 Main Street Anywhere, USA

Pregnancy information used in risk calculations:

US Date: 9/26/2012

NT: 1.8 mm

CRL: 75.3 mm

Gest. Age: 13.4 wks

Sonographer: Jane Doe

# of Fetuses: 1

Weight: 132 LBS

Race: Hispanic

Age At Term: 29.0

IDDM: No

DS Hx: No

Results:

**Nuchal Translucency** 

PAPP-A

hCG

0.98 MoM

2.62 MoM

0.91 MoM

INTERPRETATION : Final result pending second trimester sample

Optimal draw dates: 10/14/2012 - 10/28/2012

	Screening Risk	Age Related Risk	Risk Cutoff
Down Syndrome	1:10,000	1:620	1:50
Trisomy 18	1:10,000	1:2,100	1:100

The second trimester specimen may be collected between 15 and 21 weeks GA. This patient's optimal date range (16-18 weeks gestation) is noted above. This test does not reliably detect other chromosomal abnormalities.

Risk assessment for open neural tube defects (ONTD) is not available in the first trimester.

Maternal screening has some level of inherent false negative and false positive results and is not a substitute for diagnostic testing. It remains standard of care to offer prenatal diagnosis to women age 35 or older at term.

Please check the patient information used in this risk assessment and call with any corrections.

Integrated Genetics is a business unit of Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

Date: 09/28/2012

Page 1 of 1